Efficacy of Anti-Interleukin-2 Receptor Antibody (Daclizumab) in Reducing the Incidence of Acute Rejection After Renal Transplantation

BACKGROUND: Acute rejection remains a major problem in renal transplantation and represents one of the most important causes of chronic allograft dysfunction and late graft loss. Daclizumab is a genetically engineered human IgG1 monoclonal antibody that binds specifically to the α chain of the inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Saghafi, Hossein, Rahbar, Khosrow, Nobakht Haghighi, Ali, Qoreishi, Mohammad, Safdari, Farshad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614279/
https://www.ncbi.nlm.nih.gov/pubmed/23573470
http://dx.doi.org/10.5812/numonthly.1806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614279/
https://www.ncbi.nlm.nih.gov/pubmed/23573470
http://dx.doi.org/10.5812/numonthly.1806

Ejemplares similares